35
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Upregulation of Cardiomyocyte Ribonucleotide Reductase Increases Intracellular 2 deoxy-ATP, Contractility, and Relaxation

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We have previously demonstrated that substitution of ATP with 2 deoxy-ATP (dATP) increased the magnitude and rate of force production at all levels of Ca 2+-mediated activation in demembranated cardiac muscle. In the current study we hypothesized that cellular [dATP] could be increased by viral-mediated over expression of the ribonucleotide reductase (Rrm1 and Rrm2) complex, which would increase contractility of adult rat cardiomyocytes. Cell length and ratiometric (fura2) Ca 2+ fluorescence were monitored by video microscopy. At 0.5 Hz stimulation, the extent of shortening was increased ~40% and maximal rate of shortening was increased ~80% in cardiomyocytes overexpressing Rrm1+Rrm2 as compared to non-transduced cardiomyocytes. The maximal rate of relaxation was also increased ~150% with Rrm1+Rrm2 over expression, resulting in decreased time to 50% relaxation over non-transduced cardiomyocytes. These differences were even more dramatic when compared to cardiomyocytes expressing GFP-only. Interestingly, Rrm1+Rrm2 over expression had no effect on minimal or maximal intracellular [Ca 2+] (Fura2 fluorescence), indicating increased contractility is primarily due to increased myofilament activity without altering Ca 2+ release from the sarcoplasmic reticulum. Additionally, functional potentiation was maintained with Rrm1+Rrm2 over expression as stimulation frequency was increased (1 Hz and 2 Hz). HPLC analysis indicated cellular [dATP] was increased by approximately 10-fold following transduction, becoming ~1.5% of the adenine nucleotide pool. Furthermore, 2% dATP was sufficient to significantly increase crossbridge binding and contractile force during sub-maximal Ca 2+ activation in demembranated cardiac muscle. These experiments demonstrate the feasibility of directly targeting the actin-myosin chemomechanical crossbridge cycle to enhance cardiac contractility and relaxation without affecting minimal or maximal Ca 2+.

          Related collections

          Most cited references43

          • Record: found
          • Abstract: found
          • Article: not found

          A simplified system for generating recombinant adenoviruses.

          Recombinant adenoviruses provide a versatile system for gene expression studies and therapeutic applications. We report herein a strategy that simplifies the generation and production of such viruses. A recombinant adenoviral plasmid is generated with a minimum of enzymatic manipulations, using homologous recombination in bacteria rather than in eukaryotic cells. After transfections of such plasmids into a mammalian packaging cell line, viral production is conveniently followed with the aid of green fluorescent protein, encoded by a gene incorporated into the viral backbone. Homogeneous viruses can be obtained from this procedure without plaque purification. This system should expedite the process of generating and testing recombinant adenoviruses for a variety of purposes.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.

            Decreased cardiac contractility is a central feature of systolic heart failure. Existing drugs increase cardiac contractility indirectly through signaling cascades but are limited by their mechanism-related adverse effects. To avoid these limitations, we previously developed omecamtiv mecarbil, a small-molecule, direct activator of cardiac myosin. Here, we show that it binds to the myosin catalytic domain and operates by an allosteric mechanism to increase the transition rate of myosin into the strongly actin-bound force-generating state. Paradoxically, it inhibits adenosine 5'-triphosphate turnover in the absence of actin, which suggests that it stabilizes an actin-bound conformation of myosin. In animal models, omecamtiv mecarbil increases cardiac function by increasing the duration of ejection without changing the rates of contraction. Cardiac myosin activation may provide a new therapeutic approach for systolic heart failure.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Regulation of cardiac Na+,Ca2+ exchange and KATP potassium channels by PIP2.

              Cardiac Na+,Ca2+ exchange is activated by a mechanism that requires hydrolysis of adenosine triphosphate (ATP) but is not mediated by protein kinases. In giant cardiac membrane patches, ATP acted to generate phosphatidylinositol-4,5-bisphosphate (PIP2) from phosphatidylinositol (PI). The action of ATP was abolished by a PI-specific phospholipase C (PLC) and recovered after addition of exogenous PI; it was reversed by a PIP2-specific PLC; and it was mimicked by exogenous PIP2. High concentrations of free Ca2+ (5 to 20 microM) accelerated reversal of the ATP effect, and PLC activity in myocyte membranes was activated with a similar Ca2+ dependence. Aluminum reversed the ATP effect by binding with high affinity to PIP2. ATP-inhibited potassium channels (KATP) were also sensitive to PIP2, whereas Na+,K+ pumps and Na+ channels were not. Thus, PIP2 may be an important regulator of both ion transporters and channels.
                Bookmark

                Author and article information

                Journal
                0262322
                4968
                J Mol Cell Cardiol
                J. Mol. Cell. Cardiol.
                Journal of molecular and cellular cardiology
                0022-2828
                1095-8584
                12 September 2011
                03 September 2011
                December 2011
                01 December 2012
                : 51
                : 6
                : 894-901
                Affiliations
                [1 ]Department of Bioengineering, University of Washington, Seattle WA 98195 USA
                [2 ]Department of Pathology, University of Washington, Seattle WA 98195 USA
                [3 ]Department of Medicine/Cardiology, University of Washington, Seattle WA 98195 USA
                [4 ]Department of Biosciences, University of Kent, Canterbury, Kent CT2 7NJ UK
                [5 ]Center for Cardiovascular Biology, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle WA 98109 USA
                Author notes
                Corresponding Author: Michael Regnier, Ph.D., University of Washington Department of Bioengineering, Institute for Stem Cell and Regenerative Medicine, Box 355061, Seattle, WA 98195-7962 USA, Phone (206) 616-4325 Fax (206) 685-3300, mregnier@ 123456u.washington.edu
                Article
                NIHMS323945
                10.1016/j.yjmcc.2011.08.026
                3208740
                21925507
                42a461e5-03b6-41f8-b25e-bd4fa5ada91f

                Open Access under CC BY 3.0 license.

                History
                Categories
                Article

                Cardiovascular Medicine
                cardiomyocyte,contractility,ribonucleotide reductase
                Cardiovascular Medicine
                cardiomyocyte, contractility, ribonucleotide reductase

                Comments

                Comment on this article